Among the other potentialpre-sensitizing drugs were CDK inhibitors, a CHEK1 inhibitor, and OTS167, whichtargets MELK and has been reported to inhibit FLT3 protein translation andsynergize with the FLT3 inhibitor gilterinib in FLT3-ITD-mutated AML (35). This evidence concerns the gene MELK and acute myeloid leukemia.